文献速递消化系统肿瘤

RAS野生型转移性结直肠癌诱导治疗缓解深度与后续维持治疗:PanaMa试验(AIO KRK 0212)分析

Depth of response of induction therapy and consecutive maintenance treatment in patients with RAS wild-type metastatic colorectal cancer: An analysis of the PanaMa trial (AIO KRK 0212).
PubMed 文献 · Eur J Cancer · 2022-10-25

PanaMa试验中248例接受维持治疗的患者有211例可评估缓解深度(DpR)。总DpR为56.5%,诱导治疗DpR(42.5%)占总DpR的75.2%。诱导治疗DpR较大与无进展生存期(PFS)和总生存期(OS)延长显著相关,但与维持治疗组别无显著相关性。

要点

  • 诱导治疗DpR占总DpR的75.2%,提示FOLFOX联合帕尼单抗诱导后可降阶梯治疗而不显著影响疗效。
  • 诱导治疗DpR较大与PFS延长显著相关(HR 0.70,95%CI 0.52-0.93,p=0.013)。
  • 诱导治疗DpR较大与OS延长显著相关(HR 0.38,95%CI 0.28-0.51,p<0.001)。

核心结论

  • PanaMa试验中总DpR与其他基于表皮生长因子受体的方案相似。
  • 诱导治疗DpR占总肿瘤缩小的四分之三,可能提示FOLFOX联合帕尼单抗诱导后可降阶梯治疗而不显著影响疗效。
  • 诱导治疗DpR对后续维持治疗疗效具有预后价值但无预测价值。

研究设计与样本

  • PanaMa试验(AIO KRK 0212)分析,评估RAS野生型转移性结直肠癌患者诱导治疗DpR对后续维持治疗的预后和预测影响。
  • 诱导治疗为六周期5-氟尿嘧啶、亚叶酸钙、奥沙利铂(FOLFOX)联合帕尼单抗。
  • 维持治疗为5-氟尿嘧啶/亚叶酸钙联合帕尼单抗或5-氟尿嘧啶/亚叶酸钙单用。
  • 接受维持治疗的248例患者中211例可评估DpR(5-氟尿嘧啶/亚叶酸钙联合帕尼单抗组n=106;5-氟尿嘧啶/亚叶酸钙单用组n=105)。
  • 中心影像学评估依据RECIST 1.1,DpR定义为特定时间间隔内肿瘤直径百分比变化,以中位DpR(</≥)作为阈值进行预后和预测分析。

主要发现

  • 所有患者总体DpR为56.5%。
  • 诱导治疗DpR为42.5%,占总DpR的75.2%。
  • 诱导治疗DpR较大与PFS延长显著相关(HR 0.70,95%CI 0.52-0.93,p=0.013)。
  • 诱导治疗DpR较大与OS延长显著相关(HR 0.38,95%CI 0.28-0.51,p<0.001)。
  • DpR与维持治疗组别无显著相关性。

临床怎么用

  • 作者认为诱导治疗DpR占总肿瘤缩小的四分之三,可能提示FOLFOX联合帕尼单抗诱导后可降阶梯治疗而不显著影响疗效。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In patients with RAS wild-type metastatic colorectal cancer, depth of response (DpR) has gained importance as a novel end-point in clinical trials. We investigated the overall DpR, as well as the prognostic and predictive impact of DpR to induction therapy (six cycles of 5-fluorouracil, leucovorin [FU/FA], oxaliplatin [FOLFOX] and panitumumab [Pmab]) on consecutive maintenance therapy (FU/FA plus Pmab or FU/FA alone) in patients treated within the PanaMa trial. METHODS: Central radiological assessment was performed according to RECIST 1.1. DpR was defined as percentage change in tumour diameter within defined time intervals (induction therapy, maintenance therapy, total course of therapy). For prognostic and predictive analyses, median DpR (</≥) served as threshold. RESULTS: Out of 248 patients receiving maintenance therapy, 211 were evaluable for DpR analyses (FU/FA + Pmab, n = 106; FU/FA alone, n = 105). The overall DpR in all patients was 56.5%. DpR of induction therapy (42.5%) accounted for the largest proportion (75.2%) of the overall DpR. While greater DpR to induction therapy was significantly associated with prolonged PFS (HR 0.70, 95% CI 0.52-0.93, p = 0.013) and OS (HR 0.38, 95% CI 0.28-0.51, p < 0.001), there was no significant correlation of DpR and maintenance treatment arm. CONCLUSIONS: In the PanaMa trial, the overall DpR was similar to DpR achieved by other epidermal growth factor receptor-based regimens. DpR to induction therapy accounted for three quarters of the total tumour shrinkage potentially suggesting that FOLFOX plus Pmab can be de-escalated following induction without substantially compromising efficacy. DpR to induction therapy was prognostic but not predictive for efficacy of consecutive maintenance therapy. CLINICAL TRIAL INFORMATION: NCT01991873.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Sommerhäuser G, Kurreck A, Beck A, et al. Depth of response of induction therapy and consecutive maintenance treatment in patients with RAS wild-type metastatic colorectal cancer: An analysis of the PanaMa trial (AIO KRK 0212). Eur J Cancer. 2022. PMID: 36399909. doi:10.1016/j.ejca.2022.09.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。